imaging

Arterial Spin Labeling (ASL) represents a modern MRI technique for measuring perfusion, which modifies the magnetization of blood water protons to serve as natural tracers.
This method is entirely non-invasive, eliminating the need for ionizing radiation or external contrast agents.
The non-invasive nature of ASL provides numerous benefits for clinical research: it allows for repeated cerebral blood flow (CBF) measurements as often as needed and is suitable for use in vulnerable groups, such as patients with renal failure or pediatric patients.

Why It Matters: ASL offers a safe and effective way to measure cerebral perfusion, making it ideal for various clinical applications.

Have you heard about ASL before? Share your thoughts and experiences with us!

Your Challenge: Transferring measurement results manually between EDC systems of different vendors—costly, error-prone, and time-consuming.
Our Solution: Automatic API transfers that send measurement results directly into your existing systems.
Your Gain: Save time, reduce errors, and streamline your workflows like never before.
For CROs, we make efficiency effortless, so you can focus on what matters: delivering value to your clients.

Just imagine…you are planning a multi-center imaging study and you can choose whichever site you want irrespective of the MR scanner they have. In SIMAB, Fraunhofer MEVIS and mediri GmbH are developing a vendor-agnostic MR sequence development framework to increase the comparability of imaging biomarkers regardless of the employed scanner equipment.
Structural imaging biomarkers as brain atrophy or lesions will be assessed as well as functional indicators of neurological diseases, e.g. brain perfusion or permeability.
SIMAB is funded by the German Ministry for Research and Education.

Today, we are filled with joy and gratitude as we celebrate our 20th anniversary.
Two decades of innovation, challenges, and successes are behind us. We are proud of what we have achieved together and extend our heartfelt thanks to our dedicated employees, loyal customers, and reliable partners for their support and trust.
Looking to the future, we are ready to explore new paths and continue developing innovative solutions that drive us forward. Together, we will shape the next years of success.

Today is International Clinical Trials Day. Let’s celebrate this event and raise awareness about clinical trials while expressing our gratitude to all clinical research professionals worldwide.

We are extremely happy to have a third sponsor on board for our ASL Network Dinner 2024 in Singapore: Quantified Imaging.
A warm welcome to Professor Michael Chappell and Dr Tom Kirk who span out their company from the University of Nottingham in 2023.

To register for the event, please click here.

More info on the sponsors: mediri, Gold Standard Phantoms, Quantified Imaging

Did you know that Parkinson’s disease is the fastest-growing brain disease? At the same time, Parkinson’s disease is so variable, almost no 2 individuals’ symptoms and progression are the same. That is why at mediri, we are working every day to improve the diagnosis and therapy of Parkinson’s disease using advanced MR Imaging and Focused Ultrasound techniques.

For more details, you can have a look at this publication on automatic planning of MR-guided transcranial focused ultrasound treatment or this review article on blood-brain barrier dysfunction imaging.

We see a rapidly increasing need for medical imaging in clinical trials and in the development of standardized imaging biomarkers. In 2022, more than 1900 clinical trials were registered in Germany. In many of them, medical imaging is used in as a primary, quantitative and surrogate biomarker.

New AI developments across the healthcare industry, with radiology at the forefront, continue to increase the need for medical imaging core lab services.
As an Imaging CRO and Core Lab, we make your image-based clinical trials more efficient, faster and safer. This is especially important when it comes to multi-center studies that place high demands on comparability of image data.

Contact us to discuss our medical imaging solutions for reliable clinical trial results.

Thank you for a great symposium in Frankfurt about clinical trial sample contracts 2.0 – Advancing implementation together. The symposium with 200 participants was jointly organized by (BVMA), Bundesverband der Pharmazeutischen Industrie, MFT Medizinischer Fakultätentag der Bundesrepublik Deutschland e.V., KKS-Netzwerk e. V. and the Verband Forschender Arzneimittelhersteller e.V. (VFA).

It was very enriching to receive new input and to have fruitful discussions. Perhaps just a small step, but an important one in making Germany more attractive as a place for clinical research.

Many thanks to Marylène Lejeune and Carlos López Pablo at Hospital Verge da la Cinta in Tortosa for hosting our PhD Candidate Yaqeen Ali for his first secondment within the BosomShield project. Yaqeen now knows a lot more about histopathologic imaging and will work on integrating these images into mTRIAL for AI-supported prediction of breast cancer relapse probability.

Click here for more information on this project: https://bosomshield.eu/